CC-90010

Phase 2Small molecule

Bristol-Myers Squibb

CC-90010 is one of 99 small molecule programs targeting Lymphoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Anaplastic AstrocytomaActive, not recruiting

GlioblastomaActive, not recruiting

LymphomaPhase 2

Active, not recruiting

Anaplastic AstrocytomaPhase 1

Active, not recruiting

GlioblastomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Velban

EEastern Cooperative Oncology Group

Preclinical

15 2

Norvir

AbbVie

Preclinical

1 3

CC-90010

Bristol-Myers Squibb

Phase 2

1 4

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 5

Nuvigil

NNuvo Research GmbH

Preclinical

1 6

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—7

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Systemic Therapy

1 9

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—10

Rhg-CSF

CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Glioblastoma1 trial

A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Participants With Newly Diagnosed Glioblastoma

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT04324840·184 enrolled

Advanced Solid Tumors1 trial

A Study of Absorption, Metabolism, and Elimination CC-90010 in Participants With Advanced Solid Tumors

Withdrawn· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT05678283

Lymphoma1 trial

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT03220347·139 enrolled

Anaplastic Astrocytoma1 trial

CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT04047303·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for CC-90010. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CC-90010 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CC-90010. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Bristol-Myers Squibb

CC-90010

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Glioblastoma1 trial

Advanced Solid Tumors1 trial

Lymphoma1 trial

Anaplastic Astrocytoma1 trial

References

Drug Info

Quick Facts

Related News